Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 43Neoplasms 24Motor Activity 12Pain, Postoperative 9Colorectal Neoplasms 9Stomach Neoplasms 8Lung Neoplasms 8Fatigue 7Anxiety Disorders 6Pain 5Carcinoma, Hepatocellular 5Rectal Neoplasms 4Polycystic Ovary Syndrome 4Leukemia, Myeloid, Acute 4Depression 4Colonic Neoplasms 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 3Stomatitis 3Squamous Cell Carcinoma of Head and Neck 3Sleep Initiation and Maintenance Disorders 3Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Malnutrition 3Liver Neoplasms 3Head and Neck Neoplasms 3Agnosia 3Vomiting 2Urinary Incontinence 2

Interventions

AZD 6244 11trametinib 4pirfenidone 3mirdametinib 2dabrafenib 2cabozantinib 2Imatinib Mesylate 2tipifarnib 1peginterferon alfa-2b 1nilotinib 1cediranib 1binimetinib 1Vinblastine 1Surveys and Questionnaires 1Sorafenib 1Pharmacokinetics 1Methotrexate 1Liquid Biopsy 1Gadolinium DTPA 1Fluorodeoxyglucose F18 1Everolimus 1Cryotherapy 1Control Groups 1Acceptance and Commitment Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibroma, Plexiform × Control Groups × Clear all
NCT05913037 2025-03-06

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 3 Active not recruiting
167 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡